Table1. Patients' baseline characteristics
Baseline
|
ACEI/ARB
(intervention)
n= 146
|
Non-ACEI/ARB
(control)
n= 208
|
Total
n= 354
|
P value
|
Age, mean (±SD)
|
56.36 (11.9)
|
40.29 (11.6)
|
46.9(14.11)
|
< 0.001
|
Male, n (%)
|
114 (78.1)
|
170 (81.7)
|
284 (80.2)
|
0.396
|
BMI, mean (±SD)
|
28.8 (6.3)
|
27.4 (7.4)
|
28(6.9)
|
0.059
|
Obesity, n (%)
|
41 (28.1)
|
40 (19.2)
|
81 (22.9)
|
0.051
|
Hypertension, n (%)
|
123 (84.2)
|
22 (10.6)
|
145 (41.0)
|
< 0.001
|
Diabetes, n (%)
|
98 (67.1)
|
42 (20.2)
|
140 (39.5)
|
< 0.001
|
Cardiovascular disease
(HF,CAD), n (%)
|
42 (28.8)
|
5 (2.4)
|
47 (13.3)
|
< 0.001
|
Stroke, n (%)
|
3 (2.1%)
|
1 (0.5)
|
4 (1.1)
|
0.168
|
Renal disease, n (%)
|
17 (11.6)
|
9 (4.3)
|
26 (7.3)
|
0.009
|
Asthma, n (%)
|
24 (11.5)
|
15 (10.3)
|
|
0.708
|
Current use of NSAIDs, n (%)
|
24 (16.4)
|
27 (13.0)
|
51 (14.4)
|
0.362
|
Number of comorbidities*, Median (IQR)
|
3.322 (1.050)
1.000 - 6.000
|
1.688 (0.990)
0 (0-1)
|
2.362 (1.295)
1.000 - 6.000
|
< 0.001
|
COVID-19 regimen
|
|
|
|
|
Supportive Care
|
105 (71.4)
|
159 (76.4)
|
264 (74.6)
|
|
Lopinavir/ritonavir
|
2 (1.4)
|
0(0)
|
2 (0.6)
|
|
Favipravir
|
2 (1.4)
|
0(0)
|
2 (0.6)
|
|
Hydroxychloroquine+Azithromycin
|
29 (19.9)
|
39(18.8)
|
68 (19.2)
|
|
Hydroxychoroquine
|
8 (5.5)
|
10(4.8)
|
18 (5.1)
|
|
*Comorbidities include: diabetes, hypertension, cardiovascular disease (heart failure/coronary artery disease), stroke, renal disease, asthma and obesity.
IQR: Interquartile range. SD: Standard deviations. ACEI: Angiotensin-converting-enzyme inhibitors. ARBs: Angiotensin II receptor blockers. COVID-19: Coronavirus disease 2019. HF: heart failure. CAD: coronary artery disease
Table 2. Propensity Score-Matching (PSM) model results
Confounders
|
ACEI/ARBs
(unmatched)
n=146
|
Non-ACEI/ARB
(unmatched)
n=208
|
SMD* before matching
|
ACEI/ARB
(matched)
n=145
|
Non-ACEI/ARB
(matched)
n=63
|
SMD*
after matching
|
Age (years), mean (±SD)
|
56.36 (11.87)
|
40.29 (11.57)
|
1.353
|
56.46 (11.84)
|
49.21 (12.54)
|
-0.083
|
BMI (kg/m2), mean (±SD)
|
28.81(6.32)
|
27.39 (7.35)
|
0.224
|
28.68 (6.13)
|
29.22 (6.58)
|
-0.229
|
Diabetes, n (%)
|
98 (67.1)
|
42 (20.2)
|
0.995
|
97 (66.9)
|
29 (46.0)
|
0.124
|
Hypertension,
N (%)
|
123 (84.2)
|
22 (10.6)
|
2.015
|
122 (84.1)
|
22 (34.9)
|
0.066
|
Renal disease,
n (%)
|
17 (11.6)
|
9 (4.3)
|
0.737
|
17 (11.7)
|
9 (14.3)
|
0.092
|
Number of Comorbidities¶, median (IQR)
|
2 (2-3)
|
0 (0-1)
|
1.217
|
2 (2-3)
|
1 (1-3)
|
-0.061
|
Propensity score matching with age, BMI, diabetes, hypertension, renal disease and number of comorbidities
¶Comorbidities include: diabetes, hypertension, cardiovascular disease (heart failure/coronary artery disease), stroke, renal disease, asthma and obesity
*Standardized mean difference
IQR: Interquartile range. SD: Standard deviation. SMD: Standardized mean difference: Angiotensin-converting enzyme inhibitors (ACE). ARB: Angiotensin II receptor blockers. BMI: body mass index
Table 3. Adjusted odds ratio for clinical outcomes among users and non-users of ACEI/ARB
Variable
|
ACEI/ARB
(unmatched)
n=146
|
Non-ACEI/ARBs
(unmatched)
n=208
|
Adjusted odds ratio†
(95% CI)
|
P value
|
Bonferroni adjustmenta
|
ACEI/ARB
(matched)
n=145
|
Non-ACEI/ARB
(matched)
n=63
|
Adjusted odds ratio‡
(95% CI)
|
P value
|
Bonferroni adjustmenta
|
Severe or critical¶,
n (%)
|
126 (86.3)
|
67 (32.2)
|
8.25 (3.32 - 20.53)
|
<0.001
|
<0.001
|
125 (86.2)
|
30 (47.6)
|
5.55 (2.41 -12.80)
|
<0.001
|
<0.001
|
ICU admission,
n (%)
|
74 (50.7)
|
23 (11.1)
|
6.76 (2.88 -15.89)
|
<0.001
|
<0.001
|
73 (50.3)
|
11 (17.5)
|
4.98 (2.02-12.21)
|
<0.001
|
0.002
|
Noninvasive Ventilation, n (%)
|
103 (70.5)
|
54 (26.0)
|
4.77 (2.15- 10.55)
|
<0.001
|
<0.001
|
103 (71.0)
|
25 (39.7)
|
3.57 (1.68- 8.80)
|
0.001
|
0.005
|
Mechanical ventilation, n (%)
|
32 (21.9)
|
13 (6.2)
|
1.68 (0.58 -4.83)
|
0.337
|
1.000
|
31 (21.4)
|
6 (9.5)
|
1.63 (0.53-4.96)
|
0.358
|
1.000
|
In-hospital death, n (%)
|
3 (2.1)
|
2 (1.0)
|
0.35 (0.03- 4.63)
|
0.427
|
1.000
|
3 (2.1)
|
2 (3.2)
|
0.48 (0.05- 4.49)
|
0.521
|
1.000
|
¶Severe or critical defined according to WHO severity definition. ICU: Intensive care unit.
†Odds ratio adjusted using logistic regression model with the following variables: age, sex, BMI, diabetes, hypertension, renal disease, number of comorbidities (that includes diabetes, hypertension, cardiovascular disease (heart failure/coronary artery disease), stroke, renal disease, asthma and obesity) and inpatient COVID-19 regimen.
‡Odds ratios adjusted using propensity score matching model
a For multiplicity correction, Bonferroni method was used to adjust the P values
Table 4. Clinical severity by comorbidity.
Variable
|
ACEI/ARB
(unmatched)
n, (%)
|
Non-ACEI/ARB
(unmatched)
n, (%)
|
Adjusted odds ratio†
(95% CI)
|
P value
|
Adjustmenta
|
ACEI/ARB
(matched)
n, (%)
|
Non-ACEI/ARB
(matched)
n, (%)
|
Adjusted odds ratio‡
(95% CI)
|
P value
|
Adjustmenta
|
DM or HTN or Renal disease
unmatched
(n= 187)
matched
(n=173)
|
135(72.2)
|
52(27.8)
|
-
|
-
|
-
|
134(77.5)
|
39(22.5)
|
-
|
-
|
-
|
Severe or critical¶, n (%)
|
117(86.7)
|
28(53.8)
|
5.34(1.87- 15.30)
|
0.002
|
0.004
|
116(86.6)
|
19(48.7)
|
5.40(2.01-14.54)
|
<0.001
|
0.003
|
DM + HTN
unmatched
(n=100)
matched
(n=99)
|
87(87)
|
13(13.0)
|
-
|
-
|
-
|
86(86.9)
|
13(13.1)
|
-
|
-
|
-
|
Severe or critical¶,
n (%)
|
81(93.1)
|
10(76.9)
|
5.54(2.00-15.34)
|
0.001
|
0.004
|
80(93)
|
10(76.9)
|
5.01(0.80 31.43)
|
0.085
|
0.339
|
DM alone
unmatched
(n=140)
matched
(n=126)
|
98(70)
|
42(30.0)
|
-
|
-
|
-
|
97(77)
|
29(23)
|
-
|
-
|
-
|
Severe or critical¶,
n (%)
|
89(90.8)
|
24(57.1)
|
5.19(1.29-20.87)
|
0.020
|
0.081
|
88(51.7)
|
15(90.7)
|
5.32(1.45-19.56)
|
0.012
|
0.047
|
HTN alone
unmatched
(n=145)
matched
(n=144)
|
123(84.8)
|
22(15.2)
|
-
|
-
|
-
|
122(84.7)
|
22(15.3)
|
-
|
-
|
-
|
Severe or critical¶, n (%)
|
108(87.8)
|
13(59.1)
|
5.72(1.69-19.32)
|
0.005
|
0.020
|
107(87.7)
|
13(59.1)
|
5.279(1.60 -17.47)
|
0.006
|
0.025
|
¶Severe or critical defined according to WHO severity definition. ICU: Intensive care unit.
†Odds ratio adjusted using logistic regression model with the following variables: age, sex, BMI, diabetes, hypertension, renal disease, number of comorbidities (that includes diabetes, hypertension, cardiovascular disease (heart failure/coronary artery disease), stroke, renal disease, asthma and obesity) and inpatient COVID-19 regimen.
a For multiplicity correction, Bonferroni method was used to adjust the P values.
DM: Diabetes; HTN: hypertension; CI: Confidence interval;